{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:38:17Z","timestamp":1792643897807,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:00:00Z","timestamp":1565049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s13760-019-01199-z","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T02:06:35Z","timestamp":1565057195000},"page":"523-533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review"],"prefix":"10.1007","volume":"119","author":[{"given":"Antoon","family":"Meylemans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"De Bleecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,6]]},"reference":[{"key":"1199_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA et al (2018) Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med 378:625\u2013635. https:\/\/doi.org\/10.1056\/NEJMoa1710504","journal-title":"N Engl J Med"},{"key":"1199_CR2","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT et al (2017) Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723\u20131732. https:\/\/doi.org\/10.1056\/NEJMoa1702752","journal-title":"N Engl J Med"},{"key":"1199_CR3","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J et al (2016) Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388:3017\u20133026. https:\/\/doi.org\/10.1016\/S0140-6736(16)31408-8","journal-title":"Lancet"},{"key":"1199_CR4","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT et al (2016) Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 86:890\u2013897. https:\/\/doi.org\/10.1212\/WNL.0000000000002445","journal-title":"Neurology"},{"key":"1199_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00415-013-6910-6","volume":"261","author":"EM Fonteyn","year":"2014","unstructured":"Fonteyn EM, Keus SH, Verstappen CC et al (2014) The effectiveness of allied health care in patients with ataxia: a systematic review. J Neurol 261:251\u2013258. https:\/\/doi.org\/10.1007\/s00415-013-6910-6","journal-title":"J Neurol"},{"key":"1199_CR6","unstructured":"Oxford Centre for Evidence-Based Medicine (2009) Oxford Centre for Evidence-based Medicine\u2014Levels of Evidence. https:\/\/www.cebm.net\/2009\/06\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/ . Accessed 28 Dec 2018"},{"key":"1199_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1212\/WNL.0b013e31825dce83","volume":"79","author":"EJ Ashman","year":"2012","unstructured":"Ashman EJ, Gronseth GS (2012) Level of evidence reviews: three years of progress. Neurology 79:13\u201314. https:\/\/doi.org\/10.1212\/WNL.0b013e31825dce83","journal-title":"Neurology"},{"key":"1199_CR8","unstructured":"Ryan R, Hill S (2016) How to GRADE the quality of the evidence. La Trobe University, Melbourne. http:\/\/cccrg.cochrane.org\/author-resources . Accessed 28 Dec 2018"},{"key":"1199_CR9","unstructured":"US National Library of Medicine. A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02386553?term=NCT02386553&rank=1 . Accessed 21 Dec 2018"},{"key":"1199_CR10","unstructured":"US National Library of Medicine. A study to assess the safety and tolerability of nusinersen (ISIS 396443) in participants with spinal muscular atrophy (SMA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02462759?term=NCT02462759&rank=1 . Accessed 21 Dec 2018"},{"key":"1199_CR11","unstructured":"L Yan, N Kuntz, W Farwell et al (2017) Nusinersen in infants with spinal muscular atrophy(SMA): design\/interim results of the ENDEAR study. No to hattatsu. Conference: 59th annual meeting of the japanese society of child neurology, JSCN 2017. Japan, 2017, 49, S280"},{"key":"1199_CR12","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1016\/j.ejpn.2017.04.1219","volume":"21","author":"R. Finkel","year":"2017","unstructured":"R Finkel, N Kuntz, E Mercuri et al (2017) Efficacy and safety of nusinersen in infants with spinal muscular atrophy (SMA): final results from the phase 3 ENDEAR study. European journal of paediatric neurology. Conference: 12th European Paediatric Neurology Society Congress, EPNS 2017. France, 2017, 21(Supplement 1), e14\u2013e15","journal-title":"European Journal of Paediatric Neurology"},{"key":"1199_CR13","doi-asserted-by":"crossref","unstructured":"L Servais, M Farrar, RS Finkel, J Kirschner et al (2018) Nusinersen demonstrates greater efficacy in infants with shorter disease duration: end of study results from the endear study in infants with spinal muscular atrophy (SMA). Developmental medicine and child neurology. Conference: 44th annual conference of the british paediatric neurology association, BPNA 2018. United kingdom, 2017, 59(Supplement 4)","DOI":"10.1016\/j.nmd.2017.06.421"},{"key":"1199_CR14","doi-asserted-by":"crossref","unstructured":"PB Shieh, G Acsadi, W Mueller-Felber et al (2018) Safety and efficacy of nusinersen in infants\/children with spinal muscular atrophy (SMA): part 1 of the phase 2 EMBRACE study. Canadian journal of neurological sciences. Conference: 53rd annual congress of the canadian neurological sciences federation. Canada, 2018, 45(Supplement 2)","DOI":"10.1017\/cjn.2018.94"},{"key":"1199_CR15","unstructured":"N Kuntz, E Mercuri, R Finkel et al (2017) Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): end of study results from the phase 3 CHERISH study. Annals of neurology. Conference: 46th annual meeting of the child neurology society. United states, 2017, 82(Supplement 21), S264"},{"key":"1199_CR16","unstructured":"E McNeil, R Finkel, B Darras et al (2017) Nusinersen improves motor function in infants with and without permanent ventilation: results from the ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy (SMA). Annals of neurology. Conference: 46th annual meeting of the child neurology society. United states, 2017, 82(Supplement 21), S264\u2013S265"},{"key":"1199_CR17","unstructured":"R Finkel, E Mercuri, J Kirschner et al (2017) Efficacy and safety of nusinersen in children with later-onset spinal muscular atrophy (SMA): interim results of the phase 3 CHERISH study. Neurology. Conference: 69th american academy of neurology annual meeting, AAN 2017. United states, 2017, 89(8), e100\u2013e101"},{"key":"1199_CR18","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/j.ejpn.2017.04.1220","volume":"21","author":"E. Mercuri","year":"2017","unstructured":"E Mercuri, R Finkel, J Kirschner et al (2017) Interim analysis of the phase 3 CHERISH study evaluating nusinersen in patients with later-onset spinal muscular atrophy (SMA): primary and descriptive secondary endpoints. European journal of paediatric neurology. Conference: 12th european paediatric neurology society congress, EPNS 2017. France, 2017, 21(Supplement 1), e15","journal-title":"European Journal of Paediatric Neurology"},{"key":"1199_CR19","doi-asserted-by":"crossref","unstructured":"PB Shieh, G Acsadi, W Mueller-Felber (2018) Safety and efficacy of nusinersen in infants\/children with Spinal Muscular Atrophy (SMA): part 1 of the phase 2 EMBRACE study. Neurology. Conference: 70th annual meeting of the american academy of neurology, AAN 2018. United states, 2018, 90(15 Supplement 1) (no pagination)","DOI":"10.1212\/WNL.90.15_supplement.P2.324"},{"key":"1199_CR20","unstructured":"Anonymous. Emerging Science Abstracts\u201470th American Academy of Neurology Annual Meeting, AAN 2018. Neurology. Conference: 70th annual meeting of the American Academy of Neurology, AAN 2018. United states, 2018, 90(24) (no pagination)"},{"key":"1199_CR21","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/gt.2017.47","volume":"24","author":"V Christie-Brown","year":"2017","unstructured":"Christie-Brown V, Mitchell J, Talbot K (2017) The SMA Trust: the role of a disease-focused research charity in developing treatments for SMA. Gene Ther 24:544\u2013546. https:\/\/doi.org\/10.1038\/gt.2017.47","journal-title":"Gene Ther"},{"key":"1199_CR22","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/gt.2017.46","volume":"24","author":"S Jablonka","year":"2017","unstructured":"Jablonka S, Sendtner M (2017) Developmental regulation of SMN expression: pathophysiological implications and perspectives for therapy development in spinal muscular atrophy. Gene Ther 24:506\u2013513. https:\/\/doi.org\/10.1038\/gt.2017.46","journal-title":"Gene Ther"},{"key":"1199_CR23","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/gt.2017.39","volume":"24","author":"J Glascock","year":"2017","unstructured":"Glascock J, Lenz M, Hobby K, Jarecki J (2017) Cure SMA and our patient community celebrate the first approved drug for SMA. Gene Ther 24:498\u2013500. https:\/\/doi.org\/10.1038\/gt.2017.39","journal-title":"Gene Ther"},{"key":"1199_CR24","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/gt.2017.32","volume":"24","author":"NMP King","year":"2017","unstructured":"King NMP, Bishop CE (2017) New treatments for serious conditions: ethical implications. Gene Ther 24:534\u2013538. https:\/\/doi.org\/10.1038\/gt.2017.32","journal-title":"Gene Ther"},{"key":"1199_CR25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM (2017) Nusinersen: first global approval. Drugs 77:473\u2013479. https:\/\/doi.org\/10.1007\/s40265-017-0711-7","journal-title":"Drugs"},{"key":"1199_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1358\/dot.2017.53.6.2652413","volume":"53","author":"DM Paton","year":"2017","unstructured":"Paton DM (2017) Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy. Drugs Today (Barc) 53:327\u2013337. https:\/\/doi.org\/10.1358\/dot.2017.53.6.2652413","journal-title":"Drugs Today (Barc)"},{"key":"1199_CR27","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40261-017-0557-5","volume":"37","author":"V Maharshi","year":"2017","unstructured":"Maharshi V, Hasan S (2017) Nusinersen: the first option beyond supportive care for spinal muscular atrophy. Clin Drug Investig 37:807\u2013817. https:\/\/doi.org\/10.1007\/s40261-017-0557-5","journal-title":"Clin Drug Investig"},{"key":"1199_CR28","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1590\/1806-9282.64.06.484","volume":"64","author":"A Silvinato","year":"2018","unstructured":"Brazilian Medical Association, Silvinato A, Bernardo WM (2018) Spinal muscular atrophy 5Q\u2014treatment with nusinersen. Rev Assoc Med Bras (1992) 64:484\u2013491. https:\/\/doi.org\/10.1590\/1806-9282.64.06.484","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"R2","key":"1199_CR29","doi-asserted-by":"publisher","first-page":"R151","DOI":"10.1093\/hmg\/ddx215","volume":"26","author":"MJA Wood","year":"2017","unstructured":"Wood MJA, Talbot K, Bowerman M (2017) Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape. Hum Mol Genet 26(R2):R151\u2013R159. https:\/\/doi.org\/10.1093\/hmg\/ddx215","journal-title":"Hum Mol Genet"},{"key":"1199_CR30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/gt.2017.34","volume":"24","author":"NN Singh","year":"2017","unstructured":"Singh NN, Howell MD, Androphy EJ, Singh RN (2017) How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy. Gene Ther 24:520\u2013526. https:\/\/doi.org\/10.1038\/gt.2017.34","journal-title":"Gene Ther"},{"key":"1199_CR31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","volume":"25","author":"CA Stein","year":"2017","unstructured":"Stein CA, Castanotto D (2017) FDA-approved oligonucleotide therapies in 2017. Mol Ther 25:1069\u20131075. https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.023","journal-title":"Mol Ther"},{"key":"1199_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/mus.25705","volume":"57","author":"KM Bishop","year":"2018","unstructured":"Bishop KM, Montes J, Finkel RS (2018) Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam-Part 2: experience from a nusinersen clinical study. Muscle Nerve 57:142\u2013146. https:\/\/doi.org\/10.1002\/mus.25705","journal-title":"Muscle Nerve"},{"key":"1199_CR33","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0883073815627882","volume":"31","author":"M Hach\u00e9","year":"2016","unstructured":"Hach\u00e9 M, Swoboda KJ, Sethna N et al (2016) Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J Child Neurol 31:899\u2013906. https:\/\/doi.org\/10.1177\/0883073815627882","journal-title":"J Child Neurol"},{"key":"1199_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-319-89689-2_2","volume":"20","author":"RN Singh","year":"2018","unstructured":"Singh RN, Singh NN (2018) Mechanism of splicing regulation of spinal muscular atrophy genes. Adv Neurobiol 20:31\u201361. https:\/\/doi.org\/10.1007\/978-3-319-89689-2_2","journal-title":"Adv Neurobiol"},{"key":"1199_CR35","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/B978-0-444-64076-5.00038-7","volume":"148","author":"ES Arnold","year":"2018","unstructured":"Arnold ES, Fischbeck KH (2018) Spinal muscular atrophy. Handb Clin Neurol 148:591\u2013601. https:\/\/doi.org\/10.1016\/B978-0-444-64076-5.00038-7","journal-title":"Handb Clin Neurol"},{"key":"1199_CR36","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/gt.2017.64","volume":"24","author":"L Xu","year":"2017","unstructured":"Xu L, Irony I, Bryan WW, Dunn B (2017) Development of gene therapies-lessons from nusinersen. Gene Ther 24:527\u2013528. https:\/\/doi.org\/10.1038\/gt.2017.64","journal-title":"Gene Ther"},{"key":"1199_CR37","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P et al (2014) Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 83:810\u2013817. https:\/\/doi.org\/10.1212\/WNL.0000000000000741","journal-title":"Neurology"},{"key":"1199_CR38","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JM O\u2019Hagen","year":"2007","unstructured":"O\u2019Hagen JM, Glanzman AM, McDermott MP et al (2007) An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord 17:693\u2013694. https:\/\/doi.org\/10.1016\/j.nmd.2007.05.009","journal-title":"Neuromuscul Disord"},{"key":"1199_CR39","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1177\/0883073811420294","volume":"26","author":"AM Glanzman","year":"2011","unstructured":"Glanzman AM, O\u2019Hagen JM, McDermott MP et al (2011) Validation of the expanded hammersmith functional motor scale in spinal muscular atrophy type II and III. J Child Neurol 26:1499\u20131507. https:\/\/doi.org\/10.1177\/0883073811420294","journal-title":"J Child Neurol"},{"key":"1199_CR40","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J et al (2017) Revised upper limb module for spinal muscular atrophy: development of a new module. Musc Nerve 55:869\u2013874. https:\/\/doi.org\/10.1002\/mus.25430","journal-title":"Musc Nerve"},{"key":"1199_CR41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02379.x","volume":"450","author":"WHO Multicentre Growth Reference Study Group","year":"2006","unstructured":"WHO Multicentre Growth Reference Study Group (2006) WHO Motor Development Study: windows of achievement for six gross motor development milestones. Acta Paediatr Suppl 450:86\u201395. https:\/\/doi.org\/10.1111\/j.1651-2227.2006.tb02379.x","journal-title":"Acta Paediatr Suppl"},{"key":"1199_CR42","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","volume":"22","author":"CH Wang","year":"2007","unstructured":"Wang CH, Finkel RS, Bertini ES et al (2007) Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 22:1027\u20131049. https:\/\/doi.org\/10.1177\/0883073807305788","journal-title":"J Child Neurol"},{"key":"1199_CR43","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1212\/01.wnl.0000290830.40544.b9","volume":"69","author":"M Oskoui","year":"2007","unstructured":"Oskoui M, Levy G, Garland CJ et al (2007) The changing natural history of spinal muscular atrophy type 1. Neurology 69:1931\u20131936. https:\/\/doi.org\/10.1212\/01.wnl.0000290830.40544.b9","journal-title":"Neurology"},{"key":"1199_CR44","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1097\/PCC.0b013e3182388ad1","volume":"13","author":"TJ Lemoine","year":"2012","unstructured":"Lemoine TJ, Swoboda KJ, Bratton SL et al (2012) Spinal muscular atrophy type 1: are proactive respiratory interventions associated with longer survival? Pediatr Crit Care Med 13:e161\u2013165. https:\/\/doi.org\/10.1097\/PCC.0b013e3182388ad1","journal-title":"Pediatr Crit Care Med"},{"key":"1199_CR45","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1212\/WNL.0000000000006502","volume":"91","author":"D Michelson","year":"2018","unstructured":"Michelson D, Ciafaloni E, Ashwal S et al (2018) Evidence in focus: nusinersen use in spinal muscular atrophy. Neurology 91:923\u2013933. https:\/\/doi.org\/10.1212\/WNL.0000000000006502","journal-title":"Neurology"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-019-01199-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-019-01199-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-019-01199-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T14:48:16Z","timestamp":1721573296000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-019-01199-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,6]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1007\/s13760-019-01199-z","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,6]]},"assertion":[{"value":"30 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}